Health

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 – StreetInsider.com

NORTH CHICAGO, Ill., Nov. 1, 2021 /PRNewswire/ –Â AbbVie (NYSE: ABBV) today announced the presentation of new data on…

Published

4 years ago

November 1, 2021

NORTH CHICAGO, Ill., Nov. 1, 2021 /PRNewswire/ –Â AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQÂ® (upadacitinib), SKYRIZIÂ® (risankizumab) and HUMIRAÂ® (adalimumab) across multiple rheumatic diseases at the American College…

Click here to view the original article.

Related Topics:Australia StreetInsider.com

Up Next

Children Adults Equally Vulnerable to Coronavirus Infection But Children Less Likely to Become Sick – Newswise

Don't Miss

Coronavirus crisis: Which WA council areas are ahead and lagging in ‘tween’ COVID-19 vaccination race – The West Australian – Port Macquarie Online News

Noosa Online News

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 – StreetInsider.com

Health

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 – StreetInsider.com

Trending